HilleVax, Inc. (HLVX)
Total Valuation
HilleVax has a market cap or net worth of $787.26 million. The enterprise value is $533.34 million.
Market Cap | 787.26M |
Enterprise Value | 533.34M |
Important Dates
The last earnings date was Wednesday, March 20, 2024, after market close.
Earnings Date | Mar 20, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
HilleVax has 49.70 million shares outstanding. The number of shares has increased by 49.55% in one year.
Shares Outstanding | 49.70M |
Shares Change (YoY) | +49.55% |
Shares Change (QoQ) | +22.02% |
Owned by Insiders (%) | 7.45% |
Owned by Institutions (%) | 76.43% |
Float | 22.18M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 2.96 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.62, with a Debt / Equity ratio of 0.19.
Current Ratio | 10.62 |
Quick Ratio | n/a |
Debt / Equity | 0.19 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -50.66 |
Financial Efficiency
Return on equity (ROE) is -48.20% and return on invested capital (ROIC) is -42.10%.
Return on Equity (ROE) | -48.20% |
Return on Assets (ROA) | -38.10% |
Return on Capital (ROIC) | -42.10% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.37M |
Employee Count | 90 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.84% in the last 52 weeks.
Beta (1Y) | n/a |
52-Week Price Change | +0.84% |
50-Day Moving Average | 16.17 |
200-Day Moving Average | 14.60 |
Relative Strength Index (RSI) | 39.51 |
Average Volume (30 Days) | 125,513 |
Short Selling Information
The latest short interest is 474,856, so 0.96% of the outstanding shares have been sold short.
Short Interest | 474,856 |
Short Previous Month | 431,019 |
Short % of Shares Out | 0.96% |
Short % of Float | 2.14% |
Short Ratio (days to cover) | 2.58 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -133.35M |
Pretax Income | -123.57M |
Net Income | -123.57M |
EBITDA | -119.02M |
EBIT | -121.17M |
Earnings Per Share (EPS) | -$3.04 |
Balance Sheet
The company has $305.11 million in cash and $51.19 million in debt, giving a net cash position of $253.92 million or $5.11 per share.
Cash & Cash Equivalents | 305.11M |
Total Debt | 51.19M |
Net Cash | 253.92M |
Net Cash Per Share | $5.11 |
Equity / Book Value | 265.53M |
Book Value Per Share | 5.34 |
Working Capital | 281.41M |
Cash Flow
In the last 12 months, operating cash flow was -$86.78 million and capital expenditures -$10.75 million, giving a free cash flow of -$97.53 million.
Operating Cash Flow | -86.78M |
Capital Expenditures | -10.75M |
Free Cash Flow | -97.53M |
FCF Per Share | -$2.40 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
HilleVax does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -49.55% |
Shareholder Yield | -49.55% |
Earnings Yield | -15.70% |
FCF Yield | -12.39% |
Analyst Forecast
The average price target for HilleVax is $28.50, which is 82.46% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $28.50 |
Price Target Difference | 82.46% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -25.08% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |